Open access

Regional astrocyte dysregulation and altered glymphatic‐related markers in Alzheimer's disease frontal cortex

Harry Alexopoulos X. Louka E. D. de Natale Kelly Koutroubi Lisa Cashmore M. Panayotacopoulou I. Trougakos H. Wilson M. Politis

Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 40 references

Medicine

Abstract

Astrocyte dysfunction is central to Alzheimer's disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin‐4 (AQP4) and glial fibrillary acidic protein (GFAP) in post‐mortem frontal cortex of AD patients and controls across BrainNet Europe (BNE) stages.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Aug 2026

When lactate speaks: Rewiring astrocyte-neuron metabolism in Alzheimer's disease.

It is shown that a brain-penetrant GLP-1 receptor agonist rewires astrocyte-neuron metabolic coupling through lactate-driven histone lactylation, linking astrocytic glycolysis to neuronal lipid homeostasis and positioning metabolite signaling as a therapeutic axis in neurodegeneration.

Jessica Furtado, M. Schneeberger · Cell Metabolism · 0 citations

Open access Aug 2026

Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses

Alzheimer's disease (AD) features amyloid beta (Aβ) plaques and tau tangles, yet how their coexistence reshapes brain transcriptomic programs remains unclear.

Jung Hyun Park, Byungwook Kim, M. Al-Amin et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Heterogeneity of GFAP Expression in Alzheimer’s Disease: A Perspective from the Vascular-Inflammation Axis

This study systematically analyzes the pathophysiological significance of plasma glial fibrillary acidic protein (GFAP) in Alzheimer’s disease (AD) and systematically analyzes its expression heterogeneity and clinical interpretive boundaries.

Yi-Chen Chao, Yong-Chang Diwu · Journal of Artificial Intell... · 0 citations

Open access Aug 2026

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

A. Fernández-Lebrero, J. Jiménez-Balado, G. García-Escobar et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest‐old, the LifeAfter90 Study

It is hypothesized that elevated neuroinflammation, indicated by reactive astrocytosis, acts on cerebrovascular disease and separately, on amyloid beta (Aβ) pathology, to promote downstream medial temporal lobe atrophy and memory impairment.

Batool M. Rizvi, P. Maillard, A. Posis et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes

Differences in brain morphometry patterns when one or both pathologies are present remain unclear, yet differences in brain morphometry patterns when one or both pathologies are present remain unclear.

Khalid Saifullah, A. Ridwan, Arnold M. Evia et al. · Alzheimer's & Dementia · 0 citations